On November 6, 2020 Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, reported that new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, will be presented at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, being held virtually December 5-8, 2020 (Press release, Sumitomo Dainippon Pharma, NOV 6, 2020, View Source [SID1234570201]). Zella 201 is a biomarker-driven study of alvocidib followed by cytarabine and mitoxantrone in patients with relapsed/refractory MCL-1 dependent acute myeloid leukemia (AML). Data presented will include findings from an exploratory cohort of newly diagnosed, high-risk patients with MCL-1 dependent AML.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"SDP Oncology has an unwavering dedication to exploring novel approaches to oncology research and development, with the goal of addressing unmet clinical needs. We look forward to reinforcing this commitment at the ASH (Free ASH Whitepaper) Annual Meeting as we share the latest data on our diverse pipeline of investigational cancer therapeutics," said Patricia S. Andrews, CEO and Global Head of Oncology, Sumitomo Dainippon Pharma Oncology (SDP Oncology). "In particular, we are pleased to present preliminary efficacy data for the first time from this study arm which add to our growing understanding of the potential role of alvocidib combined with cytarabine and mitoxantrone in patients with MCL-1 dependent AML."
SDP Oncology and its parent company, Sumitomo Dainippon Pharma Co. Ltd., will also be presenting Phase 1 data evaluating alvocidib in combination with cytarabine and mitoxantrone in patients with relapsed/refractory AML or cytarabine and daunorubicin in patients with newly diagnosed AML. In addition, preclinical data evaluating how dubermatinib (TP-0903), an oral AXL kinase inhibitor, modulates CART19 function will be presented. Finally, SDP Oncology will be presenting details regarding the trial design of a Phase 1 study evaluating TP-3654, a PIM kinase inhibitor, in patients with intermediate-2 and high-risk primary or secondary myelofibrosis.
Below are the details for the SDP Oncology and Sumitomo Dainippon Pharma presentations:
Abstract Title
Details
Presenter
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed by Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm
Abstract #1045
Saturday, December 5 at 7:00 a.m. PST
Virtual Poster Presentation
Joshua F. Zeidner, M.D.
University of North Carolina
A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
Abstract #1251
Saturday, December 5 at 7:00 a.m. PST
Virtual Poster Presentation
Claudia Lebedinsky, M.D.
Sumitomo Dainippon Pharma Oncology, Inc.
Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models
Abstract #1430
Saturday, December 5 at 7:00 a.m. PST
Virtual Poster Presentation
Reona Sakemura, M.D., Ph.D.
Mayo Clinic, Rochester, MN
Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (pts) with Acute Myeloid Leukemia (AML)
Abstract #2831
Monday, December 7 at 7:00 a.m. PST
Virtual Poster Presentation
Yasuyoshi Morita, M.D. Kindai University, Higashiosaka, Osaka, Japan
For more information about SDP Oncology’s pipeline and clinical trials, please visit the company’s virtual booth at the ASH (Free ASH Whitepaper) Annual Meeting.
About Alvocidib
Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) currently being evaluated in the ongoing Phase 2 Zella 202 study in patients with acute myeloid leukemia (AML) who have either relapsed from or are refractory to venetoclax in combination with azacitidine or decitabine (NCT03969420). Alvocidib is also being evaluated in Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with azacitidine or decitabine (NCT03593915) and in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax (NCT03441555).
About CDK9 Inhibition and MCL-1
MCL-1 is a member of the apoptosis-regulating BCL-2 family of proteins.1 In normal function, it is essential for early embryonic development and for the survival of multiple cell lineages, including lymphocytes and hematopoietic stem cells.2 MCL-1 inhibits apoptosis and sustains the survival of leukemic blasts, which may lead to relapse or resistance to treatment.1,3 The expression of MCL-1 in leukemic blasts is regulated by cyclin-dependent kinase 9 (CDK9).4,5 Because of the short half-life of MCL-1 (2-4 hours), the effects of targeting upstream pathways are expected to reduce MCL-1 levels rapidly.4 Inhibition of CDK9 has been shown to block MCL-1 transcription, resulting in the rapid downregulation of MCL-1 protein, thus restoring the normal apoptotic regulation.1
About TP-3654
TP-3654 is an investigational second-generation selective PIM kinase inhibitor currently under evaluation in a Phase 1 study in patients with myelofibrosis (NCT04176198) and a Phase 1 study in patients with advanced solid tumors (NCT03715504).
About PIM Kinase
PIM kinases are major effectors of JAK/STAT proliferative signaling downstream of multiple growth factors and cytokines.6 PIM is overexpressed in cancers and it may enhance the ability of fibroblasts to differentiate into myofibroblasts.6
About Dubermatinib (TP-0903)
Dubermatinib is an investigational oral AXL receptor tyrosine kinase (RTK) inhibitor under evaluation in a Phase 1a/b study in patients with advanced solid tumors (NCT02729298) and an ongoing study in collaboration with the Leukemia & Lymphoma Society as part of the Beat AML Clinical Trial (NCT03013998). SDP Oncology is exploring parallel clinical development paths for dubermatinib in both solid and hematologic malignancies.
About AXL Kinase
AXL belongs to the TAM (Tyro3, AXL and Mer) family of receptor tyrosine kinases and is overexpressed in many human cancers.7 It plays a key role in tumor cell proliferation, survival, metastasis, cellular adhesion, and avoidance of the immune response. The overexpression of AXL is associated with a poor patient prognosis and drug resistance.8
About Sumitomo Dainippon Pharma Oncology
Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. The company’s robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.